Detalhe da pesquisa
1.
7-Dehydrocholesterol is an endogenous suppressor of ferroptosis.
Nature
; 626(7998): 401-410, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38297129
2.
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Cancer
; 127(4): 554-559, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33141929
3.
The heat shock protein 70 inhibitor VER155008 suppresses the expression of HSP27, HOP and HSP90ß and the androgen receptor, induces apoptosis, and attenuates prostate cancer cell growth.
J Cell Biochem
; 121(1): 407-417, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31222811
4.
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood
; 131(14): 1522-1531, 2018 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29358182
5.
RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.
Haematologica
; 105(9): 2316-2326, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054056
6.
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 25(8): 1498-1504, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31002989
7.
The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Cancer
; 125(4): 586-600, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30561760
8.
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.
Blood
; 129(1): 100-104, 2017 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27784674
9.
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Blood
; 127(11): 1410-6, 2016 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755709
10.
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.
Blood
; 137(22): 3145-3148, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624009
11.
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
Blood
; 126(24): 2578-84, 2015 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26480933
12.
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
Cancer
; 122(14): 2178-85, 2016 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27143254
13.
Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness.
Blood
; 134(10): 836-840, 2019 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31340981
14.
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.
Haematologica
; 101(11): 1398-1406, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27662018
15.
Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011.
BMC Cancer
; 16(1): 936, 2016 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27919243
16.
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Lancet Oncol
; 16(1): 57-66, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25524800
17.
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
Cancer
; 121(13): 2185-92, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25809731
18.
The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.
Br J Haematol
; 169(1): 57-70, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25521164
19.
PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.
Br J Haematol
; 166(4): 529-39, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24766330
20.
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Blood
; 119(26): 6226-33, 2012 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22592608